// App-Quantinova.ai

275 : Multicenter, randomized double-blind placebo-controlled trial of definitive concurrent chemoradiotherapy plus megestrol acetate/placebo in local-advanced esophageal cancer.

Researchers

Presenter

  • Ruinuo Jia

Principal Investigators

  • Wanying Li

  • Mian Li

  • Ruonan Li

  • Dejiu Kong

  • Shuoguo Li

  • Tanyou Shan

  • Shegan Gao

Medical Centers

  • Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China

  • The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.

  • Anyang Tumor Hospital, The Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Anyang, China

  • The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.

  • The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Deep vein thrombosis

  • Esophageal Cancer

  • Venous thrombosis

  • Solid malignancies

  • Esophageal squamous carcinoma cell

Biomarkers

  • N/A

Drug/Treatment

  • Megestrol acetate

  • Adrucil injection

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved